查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
精准医疗人工智慧的全球市场（~2030 年）：按应用、适应症、工具和最终用户
市场调查报告书
商品编码
1632126

精准医疗人工智慧的全球市场（~2030 年）：按应用、适应症、工具和最终用户

AI in Precision Medicine Market by Application, Indication, Tools, & End User -Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 403 Pages | 订单完成后即时交付

价格

精准医疗人工智慧市场规模预计将从2024年的7.8亿美元成长到2030年的39.2亿美元，预测期内复合年增长率为30.7%。

诊断和预测分析的增强正在推动精准医学人工智慧市场的发展。穿戴式装置可监测患者影像和其他相关参数，在疾病出现之前就寻找疾病征兆和治疗结果。此外，转向更便宜的医疗保健服务是另一个成长要素。人工智慧提高了传统诊疗的生产力，让精准医疗变得更便宜、更广泛使用。然而，挑战包括实施成本、高品质资料的获取不足以及资料安全和隐私问题。此外，将人工智慧纳入现有医疗流程的复杂性（包括监管要求）也可能会减缓其采用速度。

调查范围
调查年份 2022-2030
基准年 2023年
预测期 2024-2030
考虑单位 金额（美元）
部分 按应用/治疗领域/组件/工具/部署/最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

“在预测期内，自然语言处理（NLP）预计将是工具中增长最快的。”

自然语言处理 (NLP) 有助于将非结构化资料与结构化资料集成，以更好地了解患者的病历并改善治疗客製化的提案。基于 NLP 的应用程式还可以透过查看大量科学资料和文献来提供简洁的报告并支持非常快速的决策，从而加快药物发明和疾病诊断的过程。随着对精准医疗整合解决方案的需求不断增长，EHR 系统的日益普及也刺激了 NLP 技术的市场。 NLP 因其适用性以及在处理各种医疗资料方面有望获得更好的结果而成为市场游戏规则的改变者。

“从最终用户来看，医疗保健提供者将在 2023 年占据最大的市场占有率”

医疗保健提供者占据了最大的份额，因为他们是用于改善诊断、治疗计划和患者结果的人工智慧工具的第一线用户。医院和诊所正在采用人工智慧平台来改善患者资料分析、治疗映射和决策。目前，人工智慧技术在医学影像、基因组学和自订医疗服务领域的采用正在迅速增加，使医疗保健提供者能够快速有效地提供客製化治疗。此外，人工智慧解决方案支出的增加以及对高效、优质医疗保健系统的需求不断增加是推动医疗保健提供者渗透市场的两个因素。

“预计亚太地区在预测期内复合年增长率最高”

由于医疗保健基础设施资源分配的加强、人工智慧技术的加速采用以及基因组研究倡议的不断增加，预计亚太地区精准医疗人工智慧市场将在预测期内实现最高的复合年增长率。中国、日本和印度等国家正依靠人工智慧等先进技术，透过政府和私人组织的努力来改变其医疗保健系统。同时，人口老化也推动了该地区的成长，对精准治疗，特别是肿瘤学和慢性病管理产生了很高的需求。此外，该地区还出现了专门从事该技术的全球和本地公司的涌入，刺激了创新和采用的速度。

本报告调查了全球精准医疗人工智慧市场，并提供了市场概况、市场成长的各种影响因素分析、技术和专利趋势、法律制度、案例研究、市场规模趋势和预测以及各种其他资讯。按细分市场和地区、竞争环境以及主要企业概况进行详细分析。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 影响客户业务的趋势/干扰
  • 产业动态
  • 生态系分析
  • 价值链分析
  • 技术分析
  • 监管分析
  • 价格分析
  • 波特五力分析
  • 专利分析
  • 主要相关利益者和采购标准
  • 最终用户分析
  • 主要会议及活动
  • 案例研究分析
  • 投资金筹措场景
  • 经营模式
  • 人工智慧/生成人工智慧对精准医疗市场的影响

第六章精准医疗的人工智慧市场：依应用分类

  • 药物发现/开发
    • 药物发现
    • 了解疾病
    • 重新利用（再利用）
    • 新药设计
    • 药物优化
    • 安全性/毒性
    • 临床开发
  • 诊断/筛检
    • 风险评估/患者分层
    • 疾病筛检
    • 疾病诊断
    • 疾病进展、分期和预后
  • 治疗
    • 治疗选择/计划
    • 治疗监测
    • 治疗后监测/随访

第七章精准医疗的人工智慧市场：依治疗领域

  • 瘤
  • 罕见疾病
  • 感染疾病
  • 神经
  • 心臟病
  • 血
  • 其他的

第八章精准医疗人工智慧市场：按组成部分

  • 软体
  • 服务

第九章精准医疗的人工智慧市场：依工具分类

  • 机器学习
    • 深度学习
    • 监督机器学习
    • 强化机器学习
    • 无监督机器学习
    • 其他的
  • 自然语言处理（NLP）
  • 上下文感知处理和计算
  • 电脑视觉
  • 影像分析
  • 其他的

第10章精准医疗的人工智慧市场：按发展划分

  • 云端基础模式
  • 本地模型
  • 混合模式

第十一章精准医疗的人工智慧市场：依最终用户分类

  • 医疗服务提供方
  • 製药和生物技术公司
  • 医疗设备/设备公司
  • 研究中心、学术机构、政府机构
  • 其他的

第十二章精准医疗的人工智慧市场：按地区划分

  • 北美洲
    • 北美：宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：宏观经济前景
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太地区：宏观经济前景
    • 日本
    • 中国
    • 印度
    • 其他的
  • 拉丁美洲
    • 拉丁美洲：宏观经济前景
    • 巴西
    • 墨西哥
    • 其他的
  • 中东/非洲
    • 中东和非洲：宏观经济前景
    • 海湾合作委员会国家
    • 其他的

第十三章竞争格局

  • 主要企业/主要企业策略
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要企业
  • 公司评估矩阵：Start-Ups企业/中小企业
  • 企业价值评估及财务指标
  • 品牌/产品比较
  • 竞争场景

第十四章 公司简介

  • 主要企业
    • NVIDIA CORPORATION
    • EXSCIENTIA
    • GOOGLE
    • ILLUMINA, INC.
    • TEMPUS AI, INC.
    • BENEVOLENTAI
    • MICROSOFT CORPORATION
    • IBM
    • GE HEALTHCARE
    • DEEP GENOMICS
    • SIEMENS HEALTHINEERS AG
    • BIOXCEL THERAPEUTICS, INC.
    • INSILICO MEDICINE
    • PATHAI, INC.
    • VERGE GENOMICS
    • GUARDANT HEALTH, INC.
    • GRAIL, INC.
    • FOUNDATION MEDICINE, INC.
    • PROSCIA INC.
    • FLATIRON HEALTH
  • 其他公司
    • PREDICTIVE ONCOLOGY
    • PAIGE AI, INC.
    • DENSITAS INC.
    • ZEPHYR AI, INC.
    • NUCLEAI, INC.

第十五章附录

Product Code: HIT 9224

The AI in precision medicine market is projected to reach USD 3.92 billion by 2030 from USD 0.78 billion in 2024, at a CAGR of 30.7% from 2024 to 2030. The market for AI in precision medicine is propelled by the enhanced diagnostics as well as predictive analytics. Wearable devices monitor patient's imaging and other related parameters and search for signs of disease, long before it shows itself, or the outcomes of treatments. Additionally, the movement towards cheaper healthcare provision is also the other factor. AI increases the productivity of conventional diagnosis and treatment procedures; thus, it makes precision medicine cheap and widely applicable. On the contrary, factors such as costs associated with implementation, inadequate access to high-quality data and issues with data security and privacy present challenges. Furthermore, the intricate nature of incorporating AI into already existing healthcare processes including regulatory requirements may also slow down its uptake.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD Million)
SegmentsBy Application, Therapeutic Area, Component, Tools, Deployment, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East Africa.

"Natural language processing (NLP) had the fastest growth rate in the AI in precision medicine market during the forecast period, by tools."

Natural Language Processing (NLP) is anticipated to register the highest growth rate within the AI in precision medicine market as a result of its efficiency in deriving meaning from adequate unstructured medical data which consist of clinical notes, research works, and patient records. NLP helps to integrate unstructured data with structured data helps to get a better view of patient's history and suggestions regarding customizing treatment are improved. For instance, Tempus utilizes NLP techniques in fresh oncology treatment plans to find trends in the use of electronic health records. Furthermore, NLP-based applications are used to provide concise reports and help in making decisions very fast by shifting through a lot of scientific data and literature which hastens the process of drug invention and the diagnosis of diseases. The growing implementation of EHR systems alongside the rising need for precision medicine integrated solutions stimulates the market for NLP technology. Its applicability in dealing with different healthcare data and promise of better results makes it a game changer in the market.

"By end user, the healthcare providers to account for largest market share in 2023."

By end user, AI in precision medicine market is bifurcated into healthcare providers, pharmaceutical & biotechnology companies, medical device/equipment companies, research centers, academic institutes, & government organizations, and others. The healthcare providers accounted for the largest share of the market for AI in precision medicine owing to the fact that they are the foremost practitioners of the AI tools used to enhance diagnosis, treatment planning and patient outcome. Hospitals and clinics employ AI platforms for patient data analysis, therapeutic mapping, and improving the quality of decision making. The current rampant deployment of the AI technology in the fields of medical imaging, genomics and custom care provision has made it possible for providers to give customized therapies in a quick and effective manner. In addition, the rising expenditure on AI solutions and the increasing demand for efficient and high quality healthcare systems are two factors that facilitate penetration of the market by healthcare providers.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The AI in precision medicine market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific's AI in precision medicine market is projected to register highest CAGR during the forecast period due to enhanced allocation of resources towards healthcare infrastructure facilities, promotion of adoption of AI technology, and growing initiatives in genomic research. Countries like China, Japan and India are turning towards advanced technologies like Artificial Intelligence to transform the health care systems in these nations, due to government and private organization efforts. At the same time, the aging population creates a high demand for precision therapeutics, especially for oncology and chronic illness management, which also promotes growth in this region. In addition, an influx of both global and local companies specializing in the technology in the region, stimulates speed of innovation and use of the technology.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
  • By Designation: Managers (40%), Directors (35%), and Others (25%)
  • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

    • NVIDIA Corporation (US)
    • Google, Inc. (US)
    • Microsoft (US)
    • IBM (US)
    • Illumina, Inc. (US)
    • Exscientia (UK)
    • Insilico Medicine (US)
    • GE Healthcare (US)
    • Tempus AI, Inc. (US)
    • Siemens Healthineers AG (Germany)
    • BioXcel Therapeutics, Inc. (US)
    • BenevolentAI (UK)
    • PathAI, Inc. (US)
    • Guardant Health (US)
    • GRAIL, Inc. (US)
    • FOUNDATION MEDICINE, INC. (US)
    • FLATIRON HEALTH (US)
    • Proscia Inc. (US)
    • DEEP GENOMICS. (Canada)
    • Verge Genomics (US)
    • Predictive Oncology (US)
    • Paige AI, Inc. (US)
    • Densitas Inc. (Canada)
    • Zephyr AI (US)
    • Iktos (France)

Research Coverage:

This research report categorizes the AI in precision medicine market by application (drug discovery & development, diagnostics & screening, and therapeutics), therapeutic area (oncology, rare diseases, infectious diseases, neurology, cardiology, haematology, and others), component (hardware, software, and services), tools (machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition), and others), deployment (cloud-based model, on-premise model, and hybrid model), end user (healthcare providers, pharmaceutical & biotechnology companies, medical device/equipment companies, research centers, academic institutes, & government organizations, and others) and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in precision medicine market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in precision medicine market. Competitive analysis of upcoming startups in the AI in precision medicine market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in precision medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers: (Rising Demand for Personalized Healthcare), restraints (Limited access to high-quality data), opportunities (Expanding genomic research), and challenges (Regulatory and ethical complexities) influencing the growth of the AI in precision medicine market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in precision medicine market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the AI in precision medicine market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the AI in precision medicine market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as NVIDIA Corporation (US), Google, Inc. (US), Microsoft (US), IBM (US), Illumina, Inc. (US), Exscientia (UK), etc. among others in AI in precision medicine market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET SHARE ESTIMATION
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OVERVIEW
  • 4.2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION
  • 4.3 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER & REGION
  • 4.4 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHIC SNAPSHOT
  • 4.5 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
  • 5.3 MARKET DYNAMICS
    • 5.3.1 DRIVERS
      • 5.3.1.1 Increase in investments in R&D and rise in demand for personalized medication
      • 5.3.1.2 Advancements in genomic research and data availability
      • 5.3.1.3 Growth in cross-industry collaborations and partnerships
      • 5.3.1.4 Role of regulatory landscape in driving AI adoption in healthcare
    • 5.3.2 RESTRAINTS
      • 5.3.2.1 Increase in data breach concerns
      • 5.3.2.2 High cost of implementation of precision medicine solutions
      • 5.3.2.3 Accuracy challenges in AI adoption for healthcare
    • 5.3.3 OPPORTUNITIES
      • 5.3.3.1 Role of predictive analytics in advancing AI for healthcare
      • 5.3.3.2 Leveraging research pipelines and new drug development for AI in healthcare
    • 5.3.4 CHALLENGES
      • 5.3.4.1 Impact of fairness and bias on AI in healthcare
      • 5.3.4.2 Interoperability challenges due to complexity of AI solutions
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
  • 5.5 INDUSTRY TRENDS
    • 5.5.1 AI'S GROWING ROLE IN PATIENT-SPECIFIC DATA INTEGRATION AND ANALYSIS
    • 5.5.2 ADVANCEMENTS IN AI-POWERED PREDICTIVE ANALYTICS FOR TREATMENT OPTIMIZATION
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 VALUE CHAIN ANALYSIS
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Predictive analytics
      • 5.8.1.2 Neural networks
      • 5.8.1.3 Knowledge graphs
      • 5.8.1.4 Cell and gene therapies
      • 5.8.1.5 AI-driven single-cell analysis
    • 5.8.2 COMPLEMENTARY TECHNOLOGY
      • 5.8.2.1 High-performance computing (HPC)
      • 5.8.2.2 Next-generation sequencing
      • 5.8.2.3 Real-world evidence/Real-world data
      • 5.8.2.4 EHR Integration
      • 5.8.2.5 Digital health platforms
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Cloud computing
      • 5.8.3.2 Blockchain technology
      • 5.8.3.3 Internet of Things (IoT) and wearables
      • 5.8.3.4 Robotics and automation
      • 5.8.3.5 3D printing for personalized implants and devices
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.2 REGULATORY SCENARIO
  • 5.10 PRICING ANALYSIS
    • 5.10.1 INDICATIVE PRICING FOR KEY PLAYERS
    • 5.10.2 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 PATENT ANALYSIS
    • 5.12.1 PATENT PUBLICATION TRENDS
    • 5.12.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE
    • 5.12.3 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.13.2 KEY BUYING CRITERIA
  • 5.14 END-USER ANALYSIS
    • 5.14.1 UNMET NEEDS
    • 5.14.2 END-USER EXPECTATIONS
  • 5.15 KEY CONFERENCES & EVENTS
  • 5.16 CASE STUDY ANALYSIS
    • 5.16.1 SANOFI LEVERAGED AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE
    • 5.16.2 IBM'S AI-DRIVEN SOLUTION IMPROVED CLINICAL TRIAL ENROLLMENT AT MAYO CLINIC BY ENHANCING PATIENT MATCHING
    • 5.16.3 ENHANCING PATIENT IDENTIFICATION FOR RARE ONCOLOGY BIOMARKERS THROUGH GENOMIC TESTING AND STRATEGIC COLLABORATION
  • 5.17 INVESTMENT AND FUNDING SCENARIO
  • 5.18 BUSINESS MODELS
  • 5.19 IMPACT OF AI/GEN AI IN PRECISION MEDICINE MARKET
    • 5.19.1 KEY USE CASES
    • 5.19.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
      • 5.19.2.1 Enhancing patient outcomes with AI-driven predictive analytics at Johns Hopkins Hospital
    • 5.19.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.19.3.1 AI in drug discovery market
      • 5.19.3.2 Genomics market
      • 5.19.3.3 Artificial intelligence market
      • 5.19.3.4 Pharmacogenomics market
    • 5.19.4 USER READINESS AND IMPACT ASSESSMENT
      • 5.19.4.1 User readiness
        • 5.19.4.1.1 Healthcare providers
        • 5.19.4.1.2 Pharmaceutical & biotechnology companies

6 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION

  • 6.1 INTRODUCTION
  • 6.2 DRUG DISCOVERY & DEVELOPMENT
    • 6.2.1 DRUG DISCOVERY
    • 6.2.2 UNDERSTANDING DISEASES
      • 6.2.2.1 Rise in data mining to link targets to diseases
    • 6.2.3 DRUG REPURPOSING
      • 6.2.3.1 Use of graphs for targeted approach to reduce timelines and costs
    • 6.2.4 DE NOVO DRUG DESIGN
      • 6.2.4.1 Availability of large-scale biomedical datasets and urgent demand for novel treatments for complex diseases
    • 6.2.5 DRUG OPTIMIZATION
      • 6.2.5.1 Need to process extensive data on molecular properties, target interactions, and clinical outcomes
    • 6.2.6 SAFETY & TOXICITY
      • 6.2.6.1 Building generalizable model for toxicity and off-target effect prediction
    • 6.2.7 CLINICAL DEVELOPMENT
      • 6.2.7.1 Designing and conducting clinical trials for personalized dosing, targeted therapies
  • 6.3 DIAGNOSTICS & SCREENING
    • 6.3.1 RISK ASSESSMENT & PATIENT STRATIFICATION
      • 6.3.1.1 Leveraging AI to personalize treatment plan
    • 6.3.2 DISEASE SCREENING
      • 6.3.2.1 Leveraging machine learning to peruse and resolve complex patient data
    • 6.3.3 DISEASE DIAGNOSIS
      • 6.3.3.1 Identifying biomarkers for precise treatment
    • 6.3.4 DISEASE PROGRESSION, STAGING, AND PROGNOSIS
      • 6.3.4.1 Using AI to track disease conditions
  • 6.4 THERAPEUTICS
    • 6.4.1 THERAPY SELECTION & PLANNING
      • 6.4.1.1 Leveraging generative models to predict and design suitable treatment
    • 6.4.2 THERAPY MONITORING
      • 6.4.2.1 Need to effectively track safety and efficacy of treatment
    • 6.4.3 POST-TREATMENT SURVEILLANCE & FOLLOW-UP
      • 6.4.3.1 AI algorithms to identify subtle patterns in data, allowing for early detection of potential issues

7 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA

  • 7.1 INTRODUCTION
  • 7.2 ONCOLOGY
    • 7.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS
  • 7.3 RARE DISEASES
    • 7.3.1 COMBATING CHALLENGING THERAPEUTICS DUE TO COMPLEX AND HETEROGENEOUS NATURE OF RARE DISEASES
  • 7.4 INFECTIOUS DISEASES
    • 7.4.1 NEED FOR INNOVATION IN INFECTIOUS DISEASE TREATMENT, ESPECIALLY AFTER IMPACT OF COVID-19
  • 7.5 NEUROLOGY
    • 7.5.1 SHORTAGE AND COMPLEXITY OF NEURODEGENERATIVE DISEASES
  • 7.6 CARDIOLOGY
    • 7.6.1 WIDE RANGE AND INCIDENCE OF CARDIOVASCULAR DISEASES
  • 7.7 HEMATOLOGY
    • 7.7.1 AI-DRIVEN ALGORITHMS TO ANALYZE BLOOD SAMPLES, IMAGING DATA, AND GENOMIC PROFILES TO DETECT ABNORMALITIES
  • 7.8 OTHER THERAPEUTIC AREAS

8 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT

  • 8.1 INTRODUCTION
  • 8.2 SOFTWARE
    • 8.2.1 SCALABILITY AND FLEXIBILITY OF AI SOFTWARE TO ENHANCE EFFICIENCY OF CLINICAL WORKFLOWS
  • 8.3 SERVICES
    • 8.3.1 NEED FOR EXPERT ASSISTANCE AMONG HEALTHCARE ORGANIZATIONS IN ADOPTING AND OPTIMIZING AI TECHNOLOGIES

9 AI IN PRECISION MEDICINE MARKET, BY TOOL

  • 9.1 INTRODUCTION
  • 9.2 MACHINE LEARNING
    • 9.2.1 DEEP LEARNING
      • 9.2.1.1 Convolutional neural networks
        • 9.2.1.1.1 Interpreting complex biological data to enable personalizing healthcare
      • 9.2.1.2 Recurrent neural networks (RNNs)
        • 9.2.1.2.1 Optimizing clinical data to model patient trajectories by analyzing longitudinal data
      • 9.2.1.3 Generative adversarial networks (GANs)
        • 9.2.1.3.1 GAN to focus on new molecules and biological datasets
      • 9.2.1.4 Graph neural networks (GNNs)
        • 9.2.1.4.1 Predicting drug-drug interactions to optimize personalized treatment
      • 9.2.1.5 Other deep learning tools
    • 9.2.2 SUPERVISED MACHINE LEARNING
    • 9.2.3 REINFORCEMENT MACHINE LEARNING
    • 9.2.4 UNSUPERVISED MACHINE LEARNING
    • 9.2.5 OTHER MACHINE LEARNING TOOLS
  • 9.3 NATURAL LANGUAGE PROCESSING
    • 9.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO BE INTERPRETED
  • 9.4 CONTEXT-AWARE PROCESSING & COMPUTING
    • 9.4.1 TAILORING PATIENT CARE IN REAL TIME TO ENHANCE PRECISION MEDICINE
  • 9.5 COMPUTER VISION
    • 9.5.1 INCREASE IN USE OF IMAGING BIOMARKERS TO SUPPORT SURGICAL PRECISION
  • 9.6 IMAGE ANALYSIS
    • 9.6.1 HARNESSING MACHINE LEARNING TO AUTOMATE TECHNIQUES SUCH AS QUANTITATIVE IMAGING AND RADIOMICS
  • 9.7 OTHER TOOLS

10 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT

  • 10.1 INTRODUCTION
  • 10.2 CLOUD-BASED MODEL
    • 10.2.1 RESEARCH COLLABORATION AND COST-EFFICIENCY OF CLOUD DEPLOYMENT
  • 10.3 ON-PREMISE MODEL
    • 10.3.1 EASIER TO SECURE PATIENT DATA AND ENSURE COMPLIANCE IN ON-PREMISE AI-DRIVEN PRECISION MEDICINE
  • 10.4 HYBRID MODEL
    • 10.4.1 HYBRID MODELS TO ENHANCE FLEXIBILITY AND SECURITY

11 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HEALTHCARE PROVIDERS
    • 11.2.1 REVOLUTIONIZING PATIENT CARE AND TREATMENT DELIVERY THROUGH ADVANCED TECHNOLOGIES
  • 11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.3.1 DRIVING DRUG DEVELOPMENT EFFICIENCY TO DESIGN ADAPTIVE TRIAL PROTOCOLS AND OPTIMIZE TREATMENT
  • 11.4 MEDICAL DEVICE & EQUIPMENT COMPANIES
    • 11.4.1 INTEGRATION OF AI IN MEDICAL DEVICES TO ENHANCE PRECISION AND PERSONALIZED HEALTHCARE
  • 11.5 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
    • 11.5.1 AI IN ACADEMIC INSTITUTES AND PUBLIC SECTOR COLLABORATIONS TO ACCELERATE INNOVATION AND RESEARCH
  • 11.6 OTHER END USERS

12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
    • 12.2.2 US
      • 12.2.2.1 US to dominate North American market with advanced regulatory system
    • 12.2.3 CANADA
      • 12.2.3.1 Emergence of new AI-based startups and high health expenditure
  • 12.3 EUROPE
    • 12.3.1 EUROPE: MACROECONOMIC OUTLOOK
    • 12.3.2 UK
      • 12.3.2.1 Favorable government R&D investment and collaborations focused on drug discovery
    • 12.3.3 GERMANY
      • 12.3.3.1 Growing R&D investment by pharma and biotech companies
    • 12.3.4 FRANCE
      • 12.3.4.1 Strong government support through investments in initiatives
    • 12.3.5 ITALY
      • 12.3.5.1 Government Initiatives addressing local healthcare challenges through studies aimed at broader precision medicine strategies
    • 12.3.6 SPAIN
      • 12.3.6.1 High investments by pharmaceutical companies
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
    • 12.4.2 JAPAN
      • 12.4.2.1 High investment in R&D and government initiatives focused on treatment outcomes
    • 12.4.3 CHINA
      • 12.4.3.1 Government funding to advance data analysis and international collaborations to develop targeted therapies
    • 12.4.4 INDIA
      • 12.4.4.1 High growth of pharmaceutical and medical device industries
    • 12.4.5 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
    • 12.5.2 BRAZIL
      • 12.5.2.1 Increase in governmental support through initiatives such as Brazilian Artificial Intelligence Plan
    • 12.5.3 MEXICO
      • 12.5.3.1 High potential to become leader in terms of readiness in technology
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Increasing emphasis on personalized medicines and developing healthcare infrastructure
    • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.3 REVENUE ANALYSIS, 2019-2023
  • 13.4 MARKET SHARE ANALYSIS, 2023
    • 13.4.1 RANKING OF KEY MARKET PLAYERS
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 13.5.5.1 Company footprint
      • 13.5.5.2 Therapeutic area footprint
      • 13.5.5.3 End user footprint
      • 13.5.5.4 Component footprint
      • 13.5.5.5 Deployment footprint
      • 13.5.5.6 Region footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
      • 13.6.5.1 Detailed list of key startup/SME players
      • 13.6.5.2 Competitive benchmarking of key emerging players/startups, by region
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 13.7.1 COMPANY VALUATION
    • 13.7.2 FINANCIAL METRICS
  • 13.8 BRAND/PRODUCT COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS
    • 13.9.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 NVIDIA CORPORATION
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products/Services/Solutions offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches
        • 14.1.1.3.2 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Right to win
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses & competitive threats
    • 14.1.2 EXSCIENTIA
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products/Services/Solutions offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches
        • 14.1.2.3.2 Deals
        • 14.1.2.3.3 Expansions
        • 14.1.2.3.4 Other developments
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Right to win
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 GOOGLE
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products/Services/Solutions offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches
        • 14.1.3.3.2 Deals
        • 14.1.3.3.3 Expansions
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Right to win
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 ILLUMINA, INC.
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products/Services/Solutions offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Right to win
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 TEMPUS AI, INC.
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products/Services/Solutions offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches
        • 14.1.5.3.2 Deals
        • 14.1.5.3.3 Expansions
        • 14.1.5.3.4 Other developments
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Right to win
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 BENEVOLENTAI
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products/Services/Solutions offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Deals
    • 14.1.7 MICROSOFT CORPORATION
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products/Services/Solutions offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Deals
    • 14.1.8 IBM
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products/Services/Solutions offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Deals
    • 14.1.9 GE HEALTHCARE
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products/Services/Solutions offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Product launches
        • 14.1.9.3.2 Deals
        • 14.1.9.3.3 Other developments
    • 14.1.10 DEEP GENOMICS
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products/Services/Solutions offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches
        • 14.1.10.3.2 Deals
        • 14.1.10.3.3 Other developments
    • 14.1.11 SIEMENS HEALTHINEERS AG
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products/Solutions/Services offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Deals
    • 14.1.12 BIOXCEL THERAPEUTICS, INC.
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products/Solutions/Services offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Deals
        • 14.1.12.3.2 Other developments
    • 14.1.13 INSILICO MEDICINE
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products/Services/Solutions offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Product launches
        • 14.1.13.3.2 Deals
        • 14.1.13.3.3 Other developments
    • 14.1.14 PATHAI, INC.
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products/Services/Solutions offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Product launches
        • 14.1.14.3.2 Deals
        • 14.1.14.3.3 Other developments
    • 14.1.15 VERGE GENOMICS
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products/Services/Solutions offered
      • 14.1.15.3 Recent developments
        • 14.1.15.3.1 Deals
    • 14.1.16 GUARDANT HEALTH, INC.
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products/Services/Solutions offered
      • 14.1.16.3 Recent developments
        • 14.1.16.3.1 Product launches
        • 14.1.16.3.2 Deals
        • 14.1.16.3.3 Other developments
    • 14.1.17 GRAIL, INC.
      • 14.1.17.1 Business overview
      • 14.1.17.2 Products/Services/Solutions offered
      • 14.1.17.3 Recent developments
        • 14.1.17.3.1 Deals
    • 14.1.18 FOUNDATION MEDICINE, INC.
      • 14.1.18.1 Business overview
      • 14.1.18.2 Products/Services/Solutions offered
      • 14.1.18.3 Recent developments
        • 14.1.18.3.1 Deals
        • 14.1.18.3.2 Other developments
    • 14.1.19 PROSCIA INC.
      • 14.1.19.1 Business overview
      • 14.1.19.2 Products/Services/Solutions offered
      • 14.1.19.3 Recent developments
        • 14.1.19.3.1 Product launches
        • 14.1.19.3.2 Deals
        • 14.1.19.3.3 Other developments
    • 14.1.20 FLATIRON HEALTH
      • 14.1.20.1 Business overview
      • 14.1.20.2 Products/Services/Solutions offered
      • 14.1.20.3 Recent developments
        • 14.1.20.3.1 Deals
        • 14.1.20.3.2 Other developments
  • 14.2 OTHER PLAYERS
    • 14.2.1 PREDICTIVE ONCOLOGY
    • 14.2.2 PAIGE AI, INC.
    • 14.2.3 DENSITAS INC.
    • 14.2.4 ZEPHYR AI, INC.
    • 14.2.5 NUCLEAI, INC.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 AI IN PRECISION MEDICINE MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET DYNAMICS: IMPACT ANALYSIS
  • TABLE 3 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021-2024
  • TABLE 4 BIGGEST HEALTHCARE SECURITY BREACHES, 2023
  • TABLE 5 AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM
  • TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 NORTH AMERICA: REGULATORY SCENARIO
  • TABLE 13 EUROPE: REGULATORY SCENARIO
  • TABLE 14 ASIA PACIFIC: REGULATORY SCENARIO
  • TABLE 15 MIDDLE EAST & AFRICA: REGULATORY SCENARIO
  • TABLE 16 LATIN AMERICA: REGULATORY SCENARIO
  • TABLE 17 INDICATIVE PRICING FOR KEY PLAYERS, 2023 (USD)
  • TABLE 18 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION, 2022-2024 (USD)
  • TABLE 19 AI IN PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 20 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE
  • TABLE 21 AI IN PRECISION MEDICINE MARKET: LIST OF PATENTS/PATENT APPLICATIONS
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS
  • TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 24 UNMET NEEDS IN AI IN PRECISION MEDICINE MARKET
  • TABLE 25 END-USER EXPECTATIONS IN AI IN PRECISION MEDICINE MARKET
  • TABLE 26 KEY CONFERENCES & EVENTS, 2024-2025
  • TABLE 27 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 28 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 29 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 30 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR UNDERSTANDING DISEASES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 31 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG REPURPOSING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 32 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DE NOVO DRUG DESIGN, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 33 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG OPTIMIZATION, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 34 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SAFETY & TOXICITY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 35 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLINICAL DEVELOPMENT, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 36 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DIAGNOSTICS & SCREENING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 37 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RISK ASSESSMENT & PATIENT STRATIFICATION, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 38 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE SCREENING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 39 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 40 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE PROGRESSION, STAGING, AND PROGNOSIS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 41 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPEUTICS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 42 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY SELECTION & PLANNING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 43 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY MONITORING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR POST-TREATMENT SURVEILLANCE & FOLLOW-UP, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 47 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 48 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 49 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 50 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOLOGY
  • TABLE 51 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CARDIOLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 52 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEMATOLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 53 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 54 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 55 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SOFTWARE, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 56 ARTIFICIAL INTELLIGENCE SERVICES IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 57 AI IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 58 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 59 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 60 DEEP LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 61 CONVOLUTIONAL NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 62 RECURRENT NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 63 GENERATIVE ADVERSARIAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 64 GRAPH NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 65 OTHER DEEP LEARNING TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 66 SUPERVISED LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 67 REINFORCEMENT LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 68 UNSUPERVISED LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 69 OTHER MACHINE LEARNING TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 70 NATURAL LANGUAGE PROCESSING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 71 CONTEXT-AWARE PROCESSING & COMPUTING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 72 COMPUTER VISION AI IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 73 IMAGE ANALYSIS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 74 OTHER AI TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 75 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 76 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLOUD-BASED MODEL, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 77 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR ON-PREMISE MODEL, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 78 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HYBRID MODEL, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 79 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 80 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 81 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 82 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR MEDICAL DEVICE & EQUIPMENT COMPANIES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 83 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 84 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
  • TABLE 85 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 91 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022-2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 93 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 94 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 95 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 96 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 97 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022-2030 (USD MILLION)
  • TABLE 98 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 102 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 103 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022-2030 (USD MILLION)
  • TABLE 104 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 109 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 110 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 111 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 114 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 115 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 116 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 117 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 121 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 122 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 123 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 127 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 128 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 129 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 130 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 131 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 132 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 133 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 134 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 135 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 136 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 137 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 138 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 139 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 140 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 141 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 142 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 143 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 144 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 145 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 146 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 147 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 155 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 156 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 157 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 158 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 159 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 160 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 161 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 162 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 163 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 164 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 165 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 166 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 167 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 168 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 169 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 170 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 171 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 172 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 173 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 174 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 175 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 176 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 177 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 178 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 179 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 180 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 181 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 182 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 183 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 184 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 185 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 186 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 187 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 188 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 189 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 190 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 191 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 192 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 193 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 194 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 195 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 196 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 197 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 198 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 199 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 200 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 201 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 202 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 203 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 204 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 205 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 206 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 207 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 208 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 209 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 210 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 211 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 212 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 213 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 214 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 215 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 216 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 217 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 218 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 219 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
  • TABLE 220 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
  • TABLE 221 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
  • TABLE 222 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 223 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI PRECISION MEDICINE MARKET, JANUARY 2021-OCTOBER 2024
  • TABLE 224 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEGREE OF COMPETITION
  • TABLE 225 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT, 2023
  • TABLE 226 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: END USER FOOTPRINT, 2023
  • TABLE 227 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPONENT FOOTPRINT, 2023
  • TABLE 228 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEPLOYMENT FOOTPRINT, 2023
  • TABLE 229 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: REGION FOOTPRINT, 2023
  • TABLE 230 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS, 2023
  • TABLE 231 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION, 2023
  • TABLE 232 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 233 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEALS, J ANUARY 2021-OCTOBER 2024
  • TABLE 234 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 235 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 236 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 237 NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 238 NVIDIA CORPORATION: PRODUCT LAUNCHES
  • TABLE 239 NVIDIA CORPORATION: DEALS
  • TABLE 240 EXSCIENTIA: COMPANY OVERVIEW
  • TABLE 241 EXSCIENTIA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 242 EXSCIENTIA: PRODUCT LAUNCHES
  • TABLE 243 EXSCIENTIA: DEALS
  • TABLE 244 EXSCIENTIA: EXPANSIONS
  • TABLE 245 EXSCIENTIA: OTHER DEVELOPMENTS
  • TABLE 246 GOOGLE: COMPANY OVERVIEW
  • TABLE 247 GOOGLE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 248 GOOGLE: PRODUCT LAUNCHES
  • TABLE 249 GOOGLE: DEALS
  • TABLE 250 GOOGLE: EXPANSIONS
  • TABLE 251 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 252 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 253 ILLUMINA, INC.: PRODUCT LAUNCHES
  • TABLE 254 ILLUMINA, INC.: DEALS
  • TABLE 255 TEMPUS: COMPANY OVERVIEW
  • TABLE 256 TEMPUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 257 TEMPUS: PRODUCT LAUNCHES
  • TABLE 258 TEMPUS: DEALS
  • TABLE 259 TEMPUS: EXPANSIONS
  • TABLE 260 TEMPUS: OTHER DEVELOPMENTS
  • TABLE 261 BENEVOLENTAI: COMPANY OVERVIEW
  • TABLE 262 BENEVOLENTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 263 BENEVOLENTAI: DEALS
  • TABLE 264 MICROSOFT CORPORATION: COMPANY OVERVIEW
  • TABLE 265 MICROSOFT CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 266 MICROSOFT CORPORATION: DEALS
  • TABLE 267 IBM: COMPANY OVERVIEW
  • TABLE 268 IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 269 IBM: DEALS
  • TABLE 270 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 271 GE HEALTHCARE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 272 GE HEALTHCARE: PRODUCT LAUNCHES
  • TABLE 273 GE HEALTHCARE: DEALS
  • TABLE 274 GE HEALTHCARE: OTHER DEVELOPMENTS
  • TABLE 275 DEEP GENOMICS: COMPANY OVERVIEW
  • TABLE 276 DEEP GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 277 DEEP GENOMICS: PRODUCT LAUNCHES
  • TABLE 278 DEEP GENOMICS: DEALS
  • TABLE 279 DEEP GENOMICS: OTHER DEVELOPMENTS
  • TABLE 280 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 281 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 282 SIEMENS HEALTHINEERS AG: DEALS
  • TABLE 283 BIOXCEL THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 284 BIOXCEL THERAPEUTICS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 285 BIOXCEL THERAPEUTICS, INC.: DEALS
  • TABLE 286 BIOXCEL THERAPEUTICS, INC.: OTHER DEVELOPMENTS
  • TABLE 287 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 288 INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 289 INSILICO MEDICINE: PRODUCT LAUNCHES
  • TABLE 290 INSILICO MEDICINE: DEALS
  • TABLE 291 INSILICO MEDICINE: OTHER DEVELOPMENTS
  • TABLE 292 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 293 PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 294 PATHAI, INC.: PRODUCT LAUNCHES
  • TABLE 295 PATHAI, INC.: DEALS
  • TABLE 296 PATHAI, INC.: OTHER DEVELOPMENTS
  • TABLE 297 VERGE GENOMICS: COMPANY OVERVIEW
  • TABLE 298 VERGE GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 299 VERGE GENOMICS: DEALS
  • TABLE 300 GUARDANT HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 301 GUARDANT HEALTH, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 302 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES
  • TABLE 303 GUARDANT HEALTH, INC.: DEALS
  • TABLE 304 GUARDANT HEALTH, INC.: OTHER DEVELOPMENTS
  • TABLE 305 GRAIL, INC.: COMPANY OVERVIEW
  • TABLE 306 GRAIL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 307 GRAIL, INC.: DEALS
  • TABLE 308 FOUNDATION MEDICINE, INC.: COMPANY OVERVIEW
  • TABLE 309 FOUNDATION MEDICINE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 310 FOUNDATION MEDICINE, INC.: DEALS
  • TABLE 311 FOUNDATION MEDICINE, INC.: OTHER DEVELOPMENTS
  • TABLE 312 PROSCIA INC.: COMPANY OVERVIEW
  • TABLE 313 PROSCIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 314 PROSCIA INC.: PRODUCT LAUNCHES
  • TABLE 315 PROSCIA INC.: DEALS
  • TABLE 316 PROSCIA INC.: OTHER DEVELOPMENTS
  • TABLE 317 FLATIRON HEALTH: COMPANY OVERVIEW
  • TABLE 318 FLATIRON HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 319 FLATIRON HEALTH: DEALS
  • TABLE 320 FLATIRON HEALTH: OTHER DEVELOPMENTS
  • TABLE 321 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
  • TABLE 322 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 323 DENSITAS INC.: COMPANY OVERVIEW
  • TABLE 324 ZEPHYR AI, INC.: COMPANY OVERVIEW
  • TABLE 325 NUCLEAI, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 AI IN PRECISION MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 STUDY YEARS CONSIDERED
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 PRIMARY SOURCES
  • FIGURE 5 INSIGHTS FROM PRIMARY EXPERTS
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE), BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 8 TOP-DOWN APPROACH
  • FIGURE 9 CAGR PROJECTIONS, BY MARKET DYNAMIC, 2024-2030
  • FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 11 DATA TRIANGULATION
  • FIGURE 12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 13 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2024 VS. 2030 (USD MILLION)
  • FIGURE 14 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2024 VS. 2030 (USD MILLION)
  • FIGURE 15 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2024 VS. 2030 (USD MILLION)
  • FIGURE 16 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2024 VS. 2030 (USD MILLION)
  • FIGURE 17 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 18 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 19 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET
  • FIGURE 20 NORTH AMERICA TO DOMINATE AI IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD
  • FIGURE 21 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 24 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 APPROVAL RATE OF PERSONALIZED MEDICINES BY US FDA, 2015-2023
  • FIGURE 26 HEALTH SECURITY BREACHES, 2009-2023
  • FIGURE 27 INDIVIDUALS AFFECTED BY HEALTHCARE SECURITY BREACHES, 2009-2023 (MILLION)
  • FIGURE 28 USE CASES FOR PREDICTIVE ANALYTICS IN HEALTHCARE
  • FIGURE 29 REVENUE SHIFT IN AI IN PRECISION MEDICINE MARKET
  • FIGURE 30 AI IN PRECISION MEDICINE MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 31 AI IN PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS, 2023
  • FIGURE 32 AI IN PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 33 JURISDICTION ANALYSIS: TOP PATENT APPLICANT COUNTRIES, JANUARY 2015-NOVEMBER 2024
  • FIGURE 34 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET, JANUARY 2015- NOVEMBER 2024
  • FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
  • FIGURE 36 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 38 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING AI IN PRECISION MEDICINE ACROSS INDUSTRIES
  • FIGURE 39 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT
  • FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT
  • FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2019-2023 (USD MILLION)
  • FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: RANKING OF KEY PLAYERS, 2023
  • FIGURE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 46 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY FOOTPRINT, 2023
  • FIGURE 47 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 49 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 50 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 51 NVIDIA CORPORATION: COMPANY SNAPSHOT
  • FIGURE 52 EXSCIENTIA: COMPANY SNAPSHOT
  • FIGURE 53 GOOGLE: COMPANY SNAPSHOT
  • FIGURE 54 ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 55 BENEVOLENTAI: COMPANY SNAPSHOT
  • FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT
  • FIGURE 57 IBM: COMPANY SNAPSHOT
  • FIGURE 58 GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 59 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
  • FIGURE 60 GUARDANT HEALTH: COMPANY SNAPSHOT